GLP-1 medications linked to diverse health outcomes and side effects

Recent clinical studies and observational data have revealed a complex profile of benefits and risks associated with GLP-1 receptor agonists, such as semaglutide and tirzepatide.

Research presented at the ANESTHESIOLOGY 2026 meeting indicates that patients taking these drugs for diabetes or weight loss experienced 11% lower odds of major cardiovascular complications—including heart attack, stroke, and death—and 8% lower odds of postoperative infections following elective surgery. Additionally, a global study published in The Lancet Psychiatry found that GLP-1 use was associated with a 24% reduction in the risk of psychiatric hospitalizations among adults with schizophrenia and type 2 diabetes.

However, new dermatological findings suggest potential side effects. A controlled study involving participants from France, the U.S., Brazil, and Mexico reported that GLP-1 users experienced nail detachment and discoloration significantly more often than controls. Users also reported higher rates of hair loss and scalp redness, suggesting a possible inflammatory component.

Beyond physical health, pharmaceutical companies like Eli Lilly are investigating GLP-1 compounds for neurological and psychiatric applications, including potential treatments for alcohol, tobacco, and opioid addiction, as well as depression and Parkinson’s disease.